Protagonist Therapeutics (PTGX) FCF Margin (2017 - 2026)
Protagonist Therapeutics (PTGX) posted FCF Margin of 87.02% for Q1 2026, up 83.21% sequentially from 518.45% in Q4 2025, and down 52775.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
Protagonist Therapeutics (PTGX) FCF Margin (2017 - 2026) Analysis & Trends
Protagonist Therapeutics has reported FCF Margin for 10 years, with the latest figure at 87.02% in Q1 2026.
- Quarterly FCF Margin fell 52775.0% year-over-year to 87.02% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 159.04% (down 32489.0% YoY) and the FY2025 annual result came in at 121.87%, up 7980.0% from the prior year.
- FCF Margin rose to 87.02% in Q1 2026 per PTGX's latest filing, from 518.45% in the prior quarter.
- Over five years, FCF Margin peaked at 6445.62% in Q2 2024 and troughed at 1621.07% in Q2 2022.
- A 5-year average of 279.58% and a median of 63.06% in 2025 frame the typical range for FCF Margin.
- The widest YoY moves for FCF Margin: up 57338 bps in 2025, down 695658 bps in 2025.
- Over 5 years, FCF Margin stood at 1621.07% in 2022, then soared by 102 bps to 33.88% in 2023, then slumped by 153 bps to 17.87% in 2024, then sank by 2801 bps to 518.45% in 2025, then soared by 83 bps to 87.02% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 87.02%, 518.45%, and 39.09% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Protagonist Therapeutics | 9.61 Bn | 9.61 Bn | - | 102.32% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 102.32% |
| Mar 31, 2026 | -87.21% |
| Dec 31, 2025 | -499.11% |
| Sep 30, 2025 | -42.98% |
| Jun 30, 2025 | -533.59% |
| Mar 31, 2025 | 440.73% |
| Dec 31, 2024 | -17.87% |
| Sep 30, 2024 | -612.47% |
| Jun 30, 2024 | 6,445.62% |
| Mar 31, 2024 | -10.85% |
| Dec 31, 2023 | 33.88% |
| Dec 31, 2022 | 166,868.42% |
| Jun 30, 2022 | -1,547.22% |
| Mar 31, 2022 | -147.50% |
| Dec 31, 2021 | -314.90% |
| Sep 30, 2021 | -279.36% |
| Jun 30, 2021 | -1,068.43% |
| Mar 31, 2021 | -466.89% |
| Dec 31, 2020 | -336.14% |
| Sep 30, 2020 | -124.77% |